Episode
Cathie Wood Sees Value in Ionis Dip | Business and Finance News
- Published
- Jul 18, 2026
- Duration seconds
- 136
- Processing state
not_requested- Canonical source
- https://sources.thednn.ai/93a91af4807d9bac
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/cathie-wood-sees-value-in-ionis-dip-business-and-finance-news.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Cathie Wood’s ARK Genomic Revolution ETF just dumped $15 million into Ionis Pharmaceuticals—right after the stock tanked 37% following a failed late-stage trial for its heart drug eplontersen. But here’s the twist: Ionis isn’t just betting on that one flop. They’ve got Tryngolza, a recently approved drug they’re now commercializing themselves—keeping bigger profits instead of licensing out. The pivot means more risk, but also higher rewards, as they slash prices to boost access and aim for cash flow break-even by 2028. With a solid pipeline including an FDA-reviewed drug for Alexander disease and pelacarsen in late-stage trials for stroke and heart attack prevention, Ionis’ RNA-targeted tech gives them a proven edge. Wood’s move? A bold, value-driven bet on Ionis’ long-term potential—despite the bumps ahead. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/93a91af4807d9bac